Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study

Kim, Minseok Albert; Jang, Heejoon; Choi, Narak; Nam, Joon Yeul; Lee, Yun Bin; Cho, Eun Ju; Lee, Jeong-Hoon; Yu, Su Jong; Kim, Hyo Cheol; Chung, Jin Wook; Yoon, Jung‐Hwan; Kim, Yoon Jun

doi:10.2147/jhc.s335879

Cited by 13 publications

(16 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More than 70% of patients with HCC cannot undergo curative surgery; locoregional therapies, including chemoembolization, radioembolization, and radioimmunotherapy, are generally used to control the progress of the disease in patients with HCC globally ( 24 – 27 ). Previous studies showed that Yttrium-90 radioembolization and radioimmunotherapy are associated with better clinical outcomes in patients with HCC ( 28 , 29 ). Cluster 3 contained 13 keywords focused on gadolinium magnetic resonance imaging (MRI) contrast agents for the diagnosis of cancer.…”

Section: Discussionmentioning

confidence: 99%

Applications of rare earth elements in cancer: Evidence mapping and scientometric analysis

Wang¹,

Li²

2022

Front. Med.

View full text Add to dashboard Cite

Cancer is one of the most important public health issues worldwide. Radiation therapy (XRT), chemotherapy, and targeted therapy are some of the main types of cancer therapy. Metals are used extensively in cancer diagnosis and therapy, and rare earth elements occupy an important niche in these areas. In recent years, an increasing number of studies have focused on the application of lanthanides in cancer diagnosis and therapy. However, no research has analyzed the current status and future trends of lanthanides in treating cancer. We downloaded data from publications from the Web of Science Core Collection. We used VOSviewer 1.16.16 software and Excel 2016 to analyze literature information, including publication years, journals, countries, institutes, authors, keywords, and co-cited references. A total of 7,849 publications were identified. The first study on the association of rare earth elements with cancer was published in 1945. However, before 1979, the number of publications per year was no more than 10. After 1980, the number of yearly publications increased. The United States was the most productive country (2,726, 34.73%), and the institution with the most frequent contributions was the Chinese Academy of Sciences (211, 2.69%). We observed close collaboration between countries and between institutes. The 7,839 publications were published in 1,579 journals, and Radiology was both the most productive journal (183, 2.33%) and cited journal (5,863 citations). A total of 33,987 authors investigated rare earth elements and cancer. Only 0.45% of the authors published more than 10 publications, and 79.07% of the authors published only one publication. Of the top 10 high-yield authors, seven were from developed countries and three were from China. However, among the top 10 co-cited authors, there was only one high-yield author. The main research topics in the application of lanthanide complex-doped nanomaterials in the diagnosis and treatment of cancer include magnetic resonance imaging contrast agents, photodynamic therapy, anticancer drug delivery, the efficacy and safety of yttrium-90 radioimmunotherapy and chemoembolization for the treatment of HCC, gadolinium magnetic resonance imaging (MRI) contrast agent for cancer diagnosis, and cerium oxide nanoparticles. In recent years, especially since 2016, the research frontiers are emerging in cerium oxide nanoparticles and photodynamic therapy. Studies related to the application of rare earth elements and cancer have significantly increased over the past 20 years. The United States contributed the most articles in the field, followed by China and Germany, and cooperation among countries was frequent. The Chinese Academy of Sciencess, Northwestern University, and Stanford University were the three most productive institutions, and cooperation among institutions was frequent. Many high-quality journals have published relevant research, but there are few highly productive journals.

show abstract

Section: Discussionmentioning

confidence: 99%

Applications of rare earth elements in cancer: Evidence mapping and scientometric analysis

Wang¹,

Li²

2022

Front. Med.

View full text Add to dashboard Cite

show abstract

“…Although TARE-Y90 has traditionally been used to treat advanced HCC, recent refinements of the technique have achieved promising response rates in solitary HCC (10). Previous studies have shown that using TARE-Y90 can attain an objective response rate of above 85% (11,12) and a downstaging rate of above 50% (13,14). These high rates enable TARE-Y90 to be used as a bridging therapy prior to resection.…”

Section: Discussionmentioning

confidence: 99%

Imaging evaluation following transarterial radioembolization with yttrium-90 microspheres downstaging hepatocellular carcinoma: the first case in China

Li¹,

Yue²,

Zhang³

et al. 2023

Quant Imaging Med Surg

View full text Add to dashboard Cite

“…More pieces of evidence also became available supporting its use in metastatic cancer to the liver, such as colorectal metastasis and melanoma (7,40). With both TACE and SIRT as the available options, comparative studies showed superior survival in among patients treated with the former (41,42). As for breast cancer with liver metastasis, only Chang et al compared TACE and SIRT in treating liver metastatic breast cancer, suggesting a longer MST (4.9 vs. 12.9 months) and fewer adverse events of SIRT (71% vs. 44%) (9).…”

Section: Discussionmentioning

confidence: 99%

Selective internal radiation therapy of metastatic breast cancer to the liver: A meta-analysis

et al. 2022

View full text Add to dashboard Cite

IntroductionThe aim of this study is to conduct a meta-analysis to assess the efficacy of yttrium-90 selective internal radiation therapy (SIRT) in treating patients with breast cancer with hepatic metastasis.MethodPubMed and The Cochrane Library were queried from establishment to January 2021. The following keywords were implemented: “breast”, “yttrium”, and “radioembolization”. The following variables and outcomes were collected: publication year, region, sample size, study design, presence of extrahepatic disease, tumor burden, infused radioactivity, breast cancer subtype, previous treatment, median survival time (MST), length of follow-up, adverse events, and radiographical response such as Response Evaluation Criteria in Solid Tumors (RECIST), modified RECIST (mRECIST), and Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST).ResultsA total of 24 studies from 14 institutions were included in the present meta-analysis. On the basis of the data from 412 patients, post-embolization MST was 9.8 [95% confidence interval (CI): 9.0–11.6] months. Patients with additional extrahepatic metastasis had a poorer survival rate compared with those with localized hepatic metastasis only (MST: 5.3 vs. 15 months, p < 0.0001). Patients with <25% liver tumor burden exhibited more promising survival than those with >25% (MST: 10.5 vs. 6.8 months, p < 0.0139). On the basis of RECIST, mRECIST, and PERCIST criteria, tumor response rate was 36% (95% CI: 26%–47%), 49% (95% CI: 34%–65%), and 47% (95% CI: 17%–78%), respectively, whereas tumor control rate was 85% (95% CI: 76%–93%), 73% (95% CI: 59%–85%), and 97% (95% CI: 91%–100%), respectively.ConclusionOn the basis of the available published evidence, SIRT is feasible and effective in treating patients with breast cancer with liver metastasis. Patients with lower hepatic tumor burden and without extrahepatic metastasis demonstrated more survival benefit. Future randomized controlled trials are warranted.

show abstract

Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study

Cited by 13 publications

References 46 publications

Applications of rare earth elements in cancer: Evidence mapping and scientometric analysis

Applications of rare earth elements in cancer: Evidence mapping and scientometric analysis

Imaging evaluation following transarterial radioembolization with yttrium-90 microspheres downstaging hepatocellular carcinoma: the first case in China

Selective internal radiation therapy of metastatic breast cancer to the liver: A meta-analysis

Contact Info

Product

Resources

About